TITLE

Biomarkers in the prediction and management of acute coronary syndromes: current perspectives

AUTHOR(S)
Gilardi, Emanuele; Iacomini, Paolo; Marsiliani, Davide; De Marco, Guido; Covino, Marcello
PUB. DATE
January 2014
SOURCE
Research Reports in Clinical Cardiology;2014, Vol. 5, p21
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A large branch of research has focused on the search for biomarkers for early detection of myocardial cell injuries. Most of these studies have evaluated patients presenting to the emergency department, underlining the need for an ideal biomarker for rapid recognition of acute coronary syndrome (ACS). In the recent past, diagnosis of ACS in the emergency department has been based mostly on clinical information and electrocardiographic findings, and markers of generic cell damage have been used to support clinical suspicion. Over the last few years, the role of markers has taken up increasingly more space in non-life-threatening conditions, confining the clinical examination of the patient to the mere waiting for results of blood tests after the electrocardiograph. Currently, the biomarkers most widely used for the diagnosis of ACS are cardiac troponins. Since their introduction into clinical practice, several generations of commercial cardiac troponin assays have been validated in analytical and clinical trials. Development of newer high-sensitivity assays seems to have improved the value of cardiac troponin as both a diagnostic and risk indicator. Several other biomarkers of ACS apart from cardiac troponin have been investigated, but most still require validation in further studies. Among these, pregnancy-associated plasma protein-A, ischemia-modified albumin, and heart-type fatty acid binding protein seem to be the most promising markers under investigation for their possible usefulness in the emergency department setting for early diagnosis of ACS. In conclusion, a multimarker approach could be the future of research. In this review, we highlight the old and new markers, especially the most studied and widely used in clinical practice in recent years, particularly those that can help the clinician to make a rapid and confident diagnosis of ACS.
ACCESSION #
94751981

 

Related Articles

  • Can Potential Acute MI Patients be Triaged Faster? Crawford, Michael H. // Hospital Medicine Alert;Mar2012, Vol. 7 Issue 1, p1 

    The article presents a reprint of the article "Can Potential Acute MI Patients be Triaged Faster?" by Michael H. Crawford, which appeared in the February 2012 issue of "Clinical Cardiology Alert." It discusses a study which examines the use of troponin kinetics in distinguishing patients with...

  • Can Potential Acute MI Patients be Triaged Faster? Crawford, Michael H. // Clinical Cardiology Alert;Feb2012, Vol. 31 Issue 2, p9 

    The author comments on a study by T. Keller and colleagues, which concluded that high sensitivity (hs) troponin I (TnI) measurements on admission and 3 hours post admission, may facilitate the early triage of suspected acute myocardial infarction (AMI) patients. He also comments on several...

  • Case of the Month. Huerter, Karina; Fogg, Erich // JAAPA: Journal of the American Academy of Physician Assistants (;May2013, Vol. 26 Issue 5, p73 

    The article describes the case of a 62-year-old white female with acute coronary syndrome (ACS). The patient experienced symptoms of bilateral ear pain that did not respond to treatment with naproxen. She underwent electrocardiography (ECG) and coronary angiography to confirm her case. She was...

  • Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary Syndrome. Jensen, Louise J. N.; Flyvbjerg, Allan; Bjerre, Mette // BioMed Research International;9/30/2015, Vol. 2015, p1 

    The receptor of advanced glycation end products (RAGE) and its ligands are linked to the pathogenesis of coronary artery disease (CAD), and circulating soluble receptor of advanced glycation end products (sRAGE), reflecting the RAGE activity, is suggested as a potential biomarker. Elevated sRAGE...

  • Management of acute coronary syndrome. Linden, Belinda // British Journal of Cardiac Nursing;Aug2013, Vol. 8 Issue 8, p363 

    The article discusses the Scottish Intercollegiate Guidelines Network guideline on the management of acute coronary syndrome. Information is presented on the early management of the disorder, as well as management within the first 12 hours and reperfusion therapy. The article also discusses...

  • ECG of the month. Regan, Martin // British Journal of Cardiac Nursing;Jul2015, Vol. 10 Issue 7, p319 

    A quiz related to the case of a 44 year old male referred to the primary percutaneous coronary intervention (PCI) service by the ambulance service who were concerned that the changes on the ECGs were not always present.

  • In suspected ACS, a diagnostic protocol using hs-TnI identified patients at low cardiac risk at 30 days. Carpenter, Christopher R. // ACP Journal Club;3/18/2014, Vol. 160 Issue 6, p1 

    The article focuses on a study related to the validation of high-sensitivity troponin I in order to assess 30-day outcomes in emergency department patients with possibility of developing acute coronary syndrome as of March 2014. It mentions the results of the Accelerated Diagnostic protocol to...

  • Probing indiscretions: contamination of cardiac troponin reagent by very high patient samples causes false-positive results. Gould, Michael J; Wilgen, Urs; Pretorius, Carel J; Ungerer, Jacobus PJ // Annals of Clinical Biochemistry;Jul2012, Vol. 49 Issue 4, p395 

    Background: Cardiac troponin (cTn) has become the standard biomarker for the diagnosis of acute coronary syndromes. False-positive cTnI results have previously been reported on the Beckman Coulter analysers, which were shown to be random, not reproducible and occurred more commonly than...

  • The Perils, Pitfalls and Opportunities of Using High Sensitivity Cardiac Troponin. Gaze, D. C. // Current Medicinal Chemistry;Aug2011, Vol. 18 Issue 23, p3442 

    Cardiac troponins (cTn) are considered to be the 'gold standard' biomarker for the diagnosis of acute coronary syndrome (ACS); a pathological spectrum which includes cardiac ischemia, angina, myocardial infarction and ultimately cardiac failure. The growing evidence base for the diagnostic and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics